A verification study of anti-obesity effects of the consumption of proteoglycan: An open-label trial - A verification study of anti-obesity effects of the consumption of proteoglycan

ORTHOMEDICO Inc.0 sites16 target enrollmentNovember 25, 2019

Overview

No summary available.

Registry

who.int

Start Date

November 25, 2019

End Date

January 31, 2020

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

•1\. Subjects who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction 2\. Subjects who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3\. Currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disease, kidney disease, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4\. Subjects who use or take "Foods for Specified Health Uses", "Foods with Functional Claims", or other functional food/beverage in daily 5\. Subjects who are currently taking medications (including herbal medicines) and supplements 6\. Subjects who are allergic to medicines and/or the test food related products 7\. Subjects who are pregnant, breast\-feeding, and planning to become pregnant 8\. Subjects who have been enrolled in other clinical trials within the last three months before the agreement to participate in this trial or plan to participate another trial during this trial 9\. Subjects who drink alcoholic beverages immoderately 10\. Subjects who are judged as ineligible to participate in the study by the physician